WilliamCCromwellMDFAHA, FNLA

PubMed

• 633 citations
  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a rando...
  Frederick J. Raal, Raul D. Santos, Dirk J. Blom, A. David Marais, Min-Ji Charng
  Lancet. 2010-03-20
• 297 citations
  LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management
  William C. Cromwell, James D. Otvos, Michelle J. Keyes, Michael J. Pencina, Lisa M. Sullivan
  Journal of Clinical Lipidology. 2007-12-01
• 35 citations
  Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data.
  Kelly D. Myers, Joshua W. Knowles, David Staszak, Michael D. Shapiro, William James Howard
  The Lancet. Digital Health. 2019-12-01

Journal Articles

• Mipomersen Preferentially Reduces Small LDL Particle Number in Patients with Hypercholesterolemia  
  Santos RD, Raal FJ, Donovan JM, Cromwell WC, Journal of Clinical Lipidology, 1/1/2015
• Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia at High Cardiovascular Risk: A Rando...  
  Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M., Journal of American College of Cardiology, 1/1/2013
• Clinical Utility of Low-density Lipoprotein Particles and Apolipoprotein B in Patients with Cardiovascular Risk  
  Ennis JL, Cromwell WC, The Journal of Family Practice, 1/1/2013
• Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk  
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, Journal of Clinical Lipidology, 1/1/2012
• Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients: Clinical Guidance from the National Lipid Association Expert Panel ...  
  Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, ..., Journal of Clinical Lipidology, 1/1/2011
• Future Issues, Public Policy, and Public Awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hype...  
  Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE, Journal of Clinical Lipidology, 1/1/2011
• Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists  
  Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S..., Journal of Clinical Lipidology, 1/1/2011
• Mipomersen, an Apolipoprotein B Synthesis Inhibitor, for Lowering of Ldl Cholesterol Concentrations in Patients with Homozygous Familial Hypercholesterolaemia: A Rando...  
  Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST, The Lancet, 1/1/2010
• Ldl Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for Ldl Management  
  Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D'Agostino RB, Journal of Clinical Lipidology, 1/1/2007
• Hdl Associations with Coronary Heart Disease: Does Measurement of Cholesterol Content Give the Best Result?  
  Cromwell WC, Journal of Clinical Lipidology, 1/1/2007
• Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy  
  Jeyarajah EJ, Cromwell WC, Otvos JD, Clin Lab Med., 1/1/2006
• Cyclodextrin-adamantanecarboxylate Inclusion Complexes: Studies of the Variation in Cavity Size  
  Cromwell WC, Bystrom K, Eftink MR, The Journal of Physical Chemistry, 1/1/1985
• Cyclodextrin-adamantanecarboxylate inclusion complexes: studies of the variation in cavity size.  
  Cromwell WC, Bystrom K, Eftink MR, Journal of Physical Chemistry
• Lipoprotein Disorders: Current Guidelines and Practical Solutions.  
  Cromwell W, Dayspring T, Richman M, International Guidelines Center
• Development of tachyphalaxis among patients taking HMG Co-A reductase inhibitors, Reply.  
  Cromwell W, Ziajka P, Am J Cardiol
• Join now to see all

Books/Book Chapters

• Lipid and Lipoprotein Disorders: Current Clinical Solutions 
  Cromwell W, Dayspring TInternational Guideline Center, Baltimore2012
• Familial Hypercholesterolemia: Current Dilemmas and Emerging Solutions in Screening and Treatment 
  Chapter: Treatment of Adults and Children with Familial Hypercholesterolemia and Evidence for Recommendations 
  Cromwell WEditors: Toth PP.2012
• Lipid and Lipoprotein Disorders: Current Clinical Solutions 
  Cromwell WC, Dayspring T, Richman MFInternational Guideline Center, Baltimore2009
• Clinical Challenges in Lipid Disorders 
  Chapter: Clinical Utilization of Advanced Lipid Testing. 
  Page 249.0 - 259.0Cromwell WCEditors: Toth PP, Sica DA.Clinical Publishing, Oxford2008
• Therapeutic Lipidology 
  Chapter: Clinical Utilization of Lipoprotein Subfractions 
  Page 321.0 - 348.0Cromwell WC, Otvos JDEditors: Davidson MH, Toth PP, Maki KC.Humana Press, Totowa2007
• Markers in Cardiology: A Case-oriented Approach 
  Chapter: Lipoprotein Subfraction Analysis Using Nuclear Magnetic Resonance Spectroscopy 
  Page 217.0 - 250.0Cromwell WC, Bays HE, Toth PPEditors: Adams JE, Apple F, Jaffe AS.Blackstone, London2007
• Establishing and Managing a Private Practice Lipid Clinic 
  Ziajka PE, Cromwell WCMosby-Wolfe, Philadelphia2000
• Lipid and Lipoprotein Disorders: Current Clinical Solutions. 
  Cromwell WC, Dayspring TInternational Guideline Center, BaltimoreEdition 2,
• Lipid and Lipoprotein Disorders: Current Clinical Solutions. 
  Cromwell WC, Dayspring T, Richman MFInternational Guidelines Center, BaltimoreEdition 1,
• Clinical Challenges in Lipid Disorders. 
  Chapter: Clinical utilization of advanced lipid testing 
  Page 249 - 259Cromwell WCEditors: Toth PP, Sica DA.Clinical Publishing, Oxford
• Therapeutic Lipidology. 
  Chapter: Clinical utilization of lipoprotein subfractions 
  Page 321 - 348Cromwell WC, Otvos JDEditors: Davidson MH, Toth PP, Maki KC.Humana Press, Totowa
• Markers in Cardiology: A Case-Oriented Approach. 
  Chapter: Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy 
  Page 217 - 250Cromwell WC, Bays HE, Toth PPEditors: Adams JE, Apple F, Jaffe AS.Blackstone, London
• Establishing and Managing A Private Practice Lipid Clinic. 
  Ziajka PE, Cromwell WCMosby-Wolfe, PhiladelphiaEdition 2,
• Join now to see all

Abstracts/Posters

• Comparison of Cardiovascular Events between Patients Achieving Low-density Lipoprotein Particle Targets and Patients Achieving Low-density Lipoprotein Cholesterol Targ...
  Toth PP, Grabner M, Punekar R, Quimbo R, Cziraky M, Pourfarzib R, Cromwell W, Winegar D, Jacobson T., Journal of the American College of Cardiology., 1/1/2015
• Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M., Journal of Clinical Lipidology, 1/1/2012
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Am Coll Cardiol, 1/1/2011
• Mipomersen, An Apolipoprotein B Synthesis Inhibitor, Reduces Small LDL Particle Number and Increases LDL Particle Size in Patients with Heterozygous Familial Hyperchol...
  Cromwell W, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M, Circulation, 1/1/2010
• P431 Mipomersen, an apo B Synthesis Inhibitor, Preferentially Reduces Small LDL Particle Number and Increases LDL Particle Size in HoFH Patients
  Cromwell W, Santos R, Blom D, Marais AD, Charng MJ, Lachmann R, Gaudet D, Tan JL, Tribble D, Flaim J, Chasan-Taber S, Donovan J, Raal F, Atherosclerosis, 1/1/2010
• Mipomersen, a First-in-class Apolipoprotein B Synthesis Inhibitor, Lowers Lipoprotein (A) In Patients with Homozygous Familial Hypercholesterolemia
  Cromwell WC, Santos RD, Blom DJ, Marais DA, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim J, Raal FJ, Charng M-J., Journal of Clinical Lipidology, 1/1/2010
• Mipomersen, a First-in-class Apolipoprotein B Synthesis Inhibitor, Lowers Lp(a) In Patients with Homozygous Familial Hypercholesterolemia and High Baseline Lp(a): Resu...
  Cromwell W, Santos R, Lachmann R, Gaudet D, Tan JL, Marais D, Raal F, Circulation, 1/1/2009
• Mipomersen, a First-in-class Apo-b Synthesis Inhibitor, Lowers Ldlc in Patients with Homozygous Familial Hypercholesterolemia: Results of a Phase III Study
  Raal F, Santos R, Niu D-M, Lachmann RH, Gaudet D, Le Tan J, Cromwell WC, Marais D, Tribble DL, Flaim JD, Crooke ST., Circulation, 1/1/2009
• LDL Particle Number is Highly Heterogeneous Among Patients With Type 2 Diabetes Mellitus At LDL Cholesterol Target Goal <100 mg/dL
  Cromwell WC, Otvos JD., Circulation, 1/1/2005
• LDL Particles, but Not LDL Cholesterol, Are Highly Elevated in the Metabolic Syndrome - Results from the Framingham Offspring Study
  Otvos J, Cromwell W, Shalaurova I, Parise H, Wilson P, Robins S, D'Agostino R, Schaefer E, Circulation, 1/1/2003
• Effects of Simvastatin and Atorvastatin on Total and Fractionated HDL Cholesterol
  Otvos J, Cromwell W, Alexander C, et al., XIIth International Symposium on Atherosclerosis, Atherosclerosis, Stockholm, Sweden, 1/1/2000
• Fluorescence Polarization Studies on the ATP Binding Site of Hexokinase
  Bhatnagar D, Cromwell WC, Roskoski R, Fed Proc, 1/1/1985
• Thermodynamic and Fluorescence Studies of the pH Dependence of the Binding of NAD+ to Liver Alcohol Dehydrogenase
  Eftink MR, Riggins M, Cromwell W, Biophys J, 1/1/1983
• Thermodynamic and fluorescence studies of the pH dependence of the binding of NAD+ to liver alcohol dehydrogenase.
  Eftink MR, Riggins M, Cromwell W, Biophys J
• Fluorescence polarization studies on the ATP binding site of hexokinase.
  Bhatnagar D, Cromwell WC, Roskoski R, Fed Proc
• Effects of simvastatin and atorvastatin on total and fractionated HDL cholesterol.
  Otvos J, Cromwell W, Alexander C, Atherosclerosis, XIIth International Symposium on Atherosclerosis, Stockholm, Sweden
• LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome – Results from the Framingham Offspring Study.
  Otvos J, Cromwell W, Shalaurova I, Parise H, Wilson P, Robins S, D’Agostino R, Schaefer E, Circulation
• LDL Particle Number is Highly Heterogeneous Among Patients With Type 2 Diabetes Mellitus At LDL Cholesterol Target Goal <100 mg/dL .
  Cromwell WC, Otvos JD, Circulation
• Mipomersen, a First-in- Class Apolipoprotein B Synthesis Inhibitor, Lowers Lp(a) in Patients With Homozygous Familial Hypercholesterolemia and High Baseline Lp(a): Res...
  Cromwell W, Santos R, Lachmann R, Gaudet D, Tan JL, Marais D, Raal F, Circulation
• Mipomersen, a First-in-Class Apo-B Synthesis Inhibitor, Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia: Results of a Phase III Study.
  Raal F, Santos R, Niu D-M, Lachmann RH, Gaudet D, Le Tan J, Cromwell WC, Marais D, Tribble DL, Flaim JD, Crooke ST, Circulation
• P431 Mipomersen, an apo B Synthesis Inhibitor, Preferentially Reduces Small LDL Particle Number and Increases LDL Particle Size in HoFH Patients.
  Cromwell W, Santos R, Blom D, Marais AD, Charng MJ, Lachmann R, Gaudet D, Tan JL, Tribble D, Flaim J, Chasan-Taber S, Donovan J, Raal F, Atherosclerosis. Supplements
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk.
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Am Coll Cardiol
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk.
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Clin Lipidology
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a rando...
  Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan- Taber S, Tribble DL, Flaim JD, Crooke ST, The Lancet
• Join now to see all

Lectures

• Evaluation and Treatment of Dyslipoproteinemia 
• Role of Lipoprotein Quantification in Evaluation and Management of Atherosclerosis 
• Pathophysiology of Atherosclerosis 
• Lipoprotein Abnormalities in the Metabolic Syndrome 
• Lipoprotein Abnormalities in Type 2 Diabetes Mellitus 
• Join now to see all